195 related articles for article (PubMed ID: 24552712)
1. Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR ζ chain expression on CD8(+) T cells in chronic hepatitis C patients.
Zeng QL; Yang B; Sun HQ; Feng GH; Jin L; Zou ZS; Zhang Z; Zhang JY; Wang FS
Mol Cells; 2014 Jan; 37(1):66-73. PubMed ID: 24552712
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients.
Cai W; Qin A; Guo P; Yan D; Hu F; Yang Q; Xu M; Fu Y; Zhou J; Tang X
J Clin Immunol; 2013 May; 33(4):798-808. PubMed ID: 23354838
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells.
Scrimini S; Pons J; Agustí A; Soriano JB; Cosio BG; Torrecilla JA; Núñez B; Córdova R; Iglesias A; Jahn A; Crespi C; Sauleda J
Respir Med; 2013 Dec; 107(12):1895-903. PubMed ID: 23993707
[TBL] [Abstract][Full Text] [Related]
7. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.
García-Samaniego J; Romero M; Granados R; Alemán R; Jorge Juan M; Suárez D; Pérez R; Castellano G; González-Portela C
World J Gastroenterol; 2013 Mar; 19(12):1943-52. PubMed ID: 23569340
[TBL] [Abstract][Full Text] [Related]
9. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
10. Early predictability of virological response in patients of chronic hepatitis-C with genotype-3, treated with pegylated interferon and ribavirin.
Umar M; Khaar HU; Khan SA; Ahmed M; Ambreen S; Minhas ZM; Nazar M
J Ayub Med Coll Abbottabad; 2014; 26(4):559-63. PubMed ID: 25672187
[TBL] [Abstract][Full Text] [Related]
11. Polarization of granulocytic myeloid-derived suppressor cells by hepatitis C core protein is mediated via IL-10/STAT3 signalling.
Wang M; Ping Y; Li Z; Li J; Zhang Z; Yue D; Chen X; Wang L; Huang L; Huang J; Yang L; Zhao X; Yang S; Li H; Shi J; Li J; Zhang Y
J Viral Hepat; 2019 Feb; 26(2):246-257. PubMed ID: 30339295
[TBL] [Abstract][Full Text] [Related]
12. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
Dogan UB; Atabay A; Akin MS; Yalaki S
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524
[TBL] [Abstract][Full Text] [Related]
13. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
14. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
Fattovich G; Covolo L; Bibert S; Askarieh G; Lagging M; Clément S; Malerba G; Pasino M; Guido M; Puoti M; Gaeta GB; Santantonio T; Raimondo G; Bruno R; Bochud PY; Donato F; Negro F;
Aliment Pharmacol Ther; 2011 May; 33(10):1162-72. PubMed ID: 21443535
[TBL] [Abstract][Full Text] [Related]
15. Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma.
Hetta HF; Zahran AM; Mansor SG; Abdel-Malek MO; Mekky MA; Abbas WA
J Med Virol; 2019 Jul; 91(7):1319-1328. PubMed ID: 30761547
[TBL] [Abstract][Full Text] [Related]
16. IFN-α-based treatment of patients with chronic HCV show increased levels of cells with myeloid-derived suppressor cell phenotype and of IDO and NOS.
Salem ML; Zidan AA; Attia M; El-Naggar RE; Nassef M; Abou El-Azm AR; El-Bate H; Yussif M; Galal S; Abo Senna M; El Demellawy M
Immunopharmacol Immunotoxicol; 2017 Aug; 39(4):188-198. PubMed ID: 28472907
[TBL] [Abstract][Full Text] [Related]
17. [The effect of cryoglobulinemia on the antiviral therapy in patients with chronic hepatitis C].
Fan XH; Wang LF; Liu LC; Yao Y; Shan Y; Lu HY; Wu CH; Xu XY; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):721-5. PubMed ID: 22409840
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection.
Pham TN; King D; Macparland SA; McGrath JS; Reddy SB; Bursey FR; Michalak TI
Gastroenterology; 2008 Mar; 134(3):812-22. PubMed ID: 18243182
[TBL] [Abstract][Full Text] [Related]
19. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
20. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection.
Wu R; Chi X; Wang X; Sun H; Lv J; Gao X; Yu G; Kong F; Xu H; Hua R; Jiang J; Sun B; Zhong J; Pan Y; Niu J
Infect Genet Evol; 2016 Apr; 39():132-140. PubMed ID: 26820907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
